# Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)

> **NCT04428502** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 127 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Enbrel

## Key facts

- **NCT ID:** NCT04428502
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-05
- **Primary completion:** 2020-08-30
- **Final completion:** 2020-08-30
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2021-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04428502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04428502, "Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04428502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*